BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $71 | -100.0% | 352,619 | +134.2% | 0.02% | -76.6% |
Q2 2023 | $310,133 | -37.5% | 150,550 | +0.1% | 0.08% | -24.5% |
Q1 2023 | $496,320 | +182.0% | 150,400 | +276.0% | 0.10% | +117.0% |
Q3 2022 | $176,000 | +114.6% | 40,000 | +33.3% | 0.05% | +42.4% |
Q2 2022 | $82,000 | – | 30,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |